Showing 4371-4380 of 6036 results for "".
- Bausch + Lomb Acquires Blink OTC Eye Drops from J&J Visionhttps://modernod.com/news/bausch-lomb-acquires-blink-eye-drops-from-jj-vision/2481709/The latest in a string of major moves by Bausch + Lomb, the company announced it is purchasing the Blink product line of eye and contact lens
- Salvat Laboratories Initiates a Pediatric Study in Europe with SVT-15473 for the Treatment of Inflammation and Pain Following Ocular Surgeryhttps://modernod.com/news/salvat-laboratories-initiates-a-pediatric-study-in-europe-with-svt-15473-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery/2481707/Salvat Laboratories has initiated a new study with SVT-15473 clobetasol to treat inflammation and pain in patients undergoing ocular surgery. The trial will include children aged 0 to 3 years with cataracts, aiming to demonstrate the drug's safety in this population. Cataracts
- Mount Sinai Launches Center for Ophthalmic Artificial Intelligence and Human Healthhttps://modernod.com/news/mount-sinai-launches-center-for-ophthalmic-artificial-intelligence-and-human-health/2481706/The Icahn School of Medicine at Mount Sinai has launched the Center for Ophthalmic Artificial Intelligence and Human Health, the first-of-its-kind in New York and one of the first in the United States. The Center is dedicated to advancing artificial intelligence (AI) in the field of ophthalm
- Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Trial of ADX‑2191 in Patients with RPhttps://modernod.com/news/aldeyra-therapeutics-announces-improvement-from-baseline-in-retinal-function-in-phase-2-clinical-trial-of-adx2191-in-patients-with-rp/2481703/Aldeyra Therapeutics announced positive topline results from the phase 2 clinical trial of intravitreal ADX-2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa (RP). Relative to baseline, the clinical trial demonstrated statistically s
- Visgenx Announces Positive Results from a Key Translational Study for its Gene Therapy Candidate for Dry AMDhttps://modernod.com/news/visgenx-announces-positive-results-from-a-key-translational-study-for-its-gene-therapy-candidate-for-dry-amd/2481700/Visgenx announced positive data from a non-human primate study. The translational study used a single subretinal injection to deliver VGX-0111 (carrying an ELOVL2 transgene) to investigate whether VGX-0111 expresses in the target tissues and causes an increase in certain very long chain
- Ciliatech Presents 2-Year Postoperative Results on New Cilio-Scleral Surgical Approach for Treating Glaucomahttps://modernod.com/news/ciliatech-presents-2-year-postoperative-results-on-new-cilio-scleral-surgical-approach-for-treating-glaucoma/2481698/Ciliatech announced it will present the preliminary results of the second 2-year postoperative clinical trial (SAFARI II) on its Cilia-scleral Interposition Device (CID) during the World Glaucoma Congress, taking place this week. Ciliatech will present results showing sta
- FDA Does Not Approve Regeneron's High-Dose Aflibercepthttps://modernod.com/news/fda-does-not-approve-regenerons-high-dose-aflibercept/2481695/Citing "an ongoing review of inspection findings at a third-party filler," the FDA declined to approve Regeneron's aflibercept 8 mg for the treatment of patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).</
- Myra Vision Announces Funding to Advance Calibreye Surgical Treatment for Glaucoma Patientshttps://modernod.com/news/myra-vision-raises-money-to-advance-calibreye-surgical-treatment-for-glaucoma-patients/2481694/Myra Vision, which is a Shifamed portfolio company, announced the closing of its $25 million Series B financing to further product development, scale manufacturing capabilities, and support first-in-human investigation of the company's Calibreye System, a novel treatm
- iOR Publishes Ophthalmic Office-Based Surgery Safety Studyhttps://modernod.com/news/ior-publishes-ophthalmic-office-based-surgery-safety-study/2481693/Office-based lens surgery can be performed safely, with adverse event rates similar to or lower than those in the published literature, according to a study published by iOR Partner
- Luminopia Raises Money to Support Full Commercial Rollout of Amblyopia Therapeutichttps://modernod.com/news/luminopia-raises-money-to-support-full-commercial-rollout-of-amblyopia-therapeutic/2481692/Luminopia announced it has raised an additional $16 million in new capital to support the full commercial rollout later this year of the company’s lead product, Luminopia, a software-based therapeutic for amblyopia, the leading cause of vision loss among children. Luminopia w